share_log

Philips expands access to hemodynamics at point-of-care for real-time blood flow assessment on Handheld Ultrasound – Lumify

Philips expands access to hemodynamics at point-of-care for real-time blood flow assessment on Handheld Ultrasound – Lumify

飛利浦擴大了在手持式超聲波上進行實時血流評估的醫療點血流動力學的渠道 — Lumify
GlobeNewswire ·  2022/02/09 22:06

Man undergoing ultrasound in ED

男子正在急診接受超聲檢查。

Product shot of Philips Lumify handheld ultrasound

飛利浦Lumify便攜式超聲設備的產品照片。


February 9, 2022


2022年2月9日

  • Philips point-of-care ultrasound technology now includes Pulse Wave Doppler for all physicians – from cardiologists and radiologists to emergency care – to quickly assess hemodynamics in cardiac function anytime, anywhere
  • Lumify is also the first and only handheld ultrasound with B-lines software and smart algorithms to enhance heart and lung assessment in severe COVID cases and more
  • 飛利浦術中超聲技術現在包括脈搏波多普勒,可供所有醫生 - 從心臟病專家和放射科醫生到急救中心 - 隨時隨地快速評估心功能的血液動力學。
  • Lumify還是第一個並且是唯一一款帶有b線軟件和智能算法的便攜式超聲設備,可加強COVID-19嚴重病例中的心肺評估。

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has expanded its ultrasound portfolio with advanced hemodynamic assessment and measurement capabilities on its handheld point-of-care ultrasound – Lumify. With the addition of Pulse Wave Doppler [1], Philips has greatly expanded the utility of its Handheld Ultrasound – Lumify – enabling clinicians to quantify blood flow in a wide range of point-of-care diagnostic applications – including cardiology, vascular, abdominal, urology, obstetrics and gynecology. Also new to Lumify are obstetric measurements to help in early assessment of gestational age and the identification of high-risk pregnancies.

荷蘭阿姆斯特丹 - 全球領先的健康科技公司飛利浦(紐交所:PHG,AEX:PHIA)今天宣佈,已在其便攜式無創超聲設備Lumify上增加了先進的血液動力學評估和測量功能。通過增加脈搏波多普勒,飛利浦大大擴展了手持式超聲設備Lumify的實用性,使臨床醫生可以量化一系列現場診斷應用程序中的血流量,包括心臟病學,血管學,腹部學,泌尿學,產科和婦科。

Point-of-care hemodynamics
Pulse Wave Doppler ultrasound provides clinicians with more information, in addition to 2D and color imaging, to assess hemodynamic patterns to differentiate between arterial and venous blood flow and quantify hemodynamic function. The resulting hemodynamic measurements can  enhance diagnostic confidence and timely clinical decision-making in virtually any care setting, including cardiology and emergency medicine. With these latest features, Philips' easy-to-use fully integrated handheld ultrasound system – Lumify – brings together imaging tools across ultrasound platforms, leveraging the company's expertise in cardiology and radiology. The Lumify system also provides clinicians with advanced analysis software and reporting tools, and access to tele-ultrasound capabilities (Lumify with Collaboration Live powered by Reacts) for live communication support to connect clinicians around the globe for real-time collaboration.

現場心血動力學檢查。
脈搏波多普勒超聲爲臨床醫生提供了更多信息,除2D和彩色成像外,還可評估血流動力學模式以區分動脈和靜脈血流並量化血流動力學功能。由此得出的血流動力學測量結果可以增強診斷的可信度,並在幾乎任何護理環境下快速做出決策,包括心臟病學和急診醫學。通過這些最新功能,飛利浦易於使用的完全集成的手持式超聲系統Lumify將超聲平台上的成像工具集合在一起,利用公司在心血管病學和放射學方面的專業知識。Lumify系統還爲臨床醫生提供了先進的分析軟件和報告工具,以及協作互動實時通信支持等。

"By applying Philips' expertise in cardiovascular care, imaging and patient monitoring to Philips Handheld Ultrasound – Lumify – we are committed to deliver a dedicated, innovative point-of-care portfolio, enabling clinicians to quickly assess hemodynamics – including cardiovascular function, organ perfusion and fetal assessment – in a daily routine, to identify abnormalities and intervene quickly," said Matthijs Groot Wassink, General Manager of Point of Care Ultrasound at Philips. "With the addition of Pulse Wave Doppler and enhanced obstetrics measurements, we have increased the number of markers on which diagnoses can be made, to deliver high quality imaging and enhance the evaluation and effectiveness of treatment in real-time."

“將飛利浦在心血管護理,影像和患者監護方面的專業知識應用於飛利浦便攜式超聲設備Lumify中,我們致力於提供專注且創新的現場診斷解決方案,使臨床醫生能夠快速評估血液動力學,包括心血管功能,器官灌注和胎兒評估,發現異常並迅速干預,”飛利浦首席超聲診斷專家Matthijs Groot Wassink表示。增加了脈搏波多普勒和增強的產科測量後,我們已經增加了可進行診斷的標記數量,以提供高質量的成像,增強實時治療評估和有效性。”

"Having Color Flow Doppler (CFD) and Pulse Wave Doppler on a handheld device is game changing, allowing clinicians to take point-of-care ultrasound examinations to the next level," said Dr. Robert Jones, Professor of Emergency Medicine at the MetroHealth System, Cleveland, Ohio in the U.S.A. Dr. Jones will discuss the clinical advantages and benefits of integrating CFD and Pulse Wave Doppler into the point-of-care ultrasound evaluation of acutely ill and injured patients in the Emergency Department in an upcoming webinar.

“在手持設備上擁有彩色多普勒血流成像和脈搏波多普勒將改變遊戲規則,使臨床醫生將超聲設備的現場檢查推向新的高度,”美國俄亥俄州克利夫蘭市MetroHealth System的急診醫學教授Robert Jones博士說。Jones博士將在即將進行的網絡研討會上討論將CFD和脈搏波多普勒融入急診科急病和傷病患者的現場超聲評估中的臨床優勢和益處。

Philips B-lines software enhances heart and lung assessments in handheld ultrasound
In addition to adding Pulse Wave Doppler for hemodynamics, Philips is the first and only point-of-care ultrasound solution with B-lines (B-line quantification tool for ultrasound lung imaging) software and intelligent algorithms to enhance heart and lung assessments, which is critical when dealing with severe COVID cases. The pandemic has shown the relevance of lung ultrasound in the diagnosis and treatment of pneumonia, one of the most common complications of COVID-19. AI-enhanced automated algorithms looking for B-lines in lung fluid can help provide more objective data and interpretation.

飛利浦'b線'軟件增強了便攜式超聲中的心肺評估。
除了增加hemodynamics的脈搏波多普勒外,飛利浦還是第一個並且是唯一一家擁有b線(超聲肺成像的b線量化工具)軟件和智能算法以增強心肺評估的便攜式超聲解決方案,在處理COVID-19嚴重病例時至關重要。該疫情已表明肺部超聲在診斷和治療肺炎方面的相關性,這是COVID-19最常見的併發症之一。AI增強的自動化算法在尋找肺液中的b線時有助於提供更客觀的數據和解釋。

Increased access to quality care
The continuous scanning, performance and portability of Philips Handheld Ultrasound – Lumify – brings a full diagnostic solution to care professionals at the bedside; both in and outside of the hospital. The innovative technology is also in widespread use in community-based mother and child care programs, providing access to quality healthcare for underserved communities worldwide, including a program in Kenya driven by the Philips Foundation to educate midwives to deliver ultrasound-based antenatal pregnancy screening in village clinics, while receiving telehealth support from radiologists at distance.

連續的掃描,性能和便攜性使飛利浦Handheld Ultrasound - Lumify - 爲牀邊的護理專業人員提供了完整的診斷解決方案;在醫院內外均可使用。創新技術在社區母嬰護理計劃中也得到廣泛使用,爲全球包括飛利浦基金會在內的未受服務社區提供了質量保障的醫療保健,其中包括一個由飛利浦基金會推動的肯尼亞計劃,旨在通過爲村莊診所提供基於超聲的產前檢查培訓,並獲得遠程放射科醫生的遠程衛生支持。
飛利浦手持式超聲 - Lumify - 的持續掃描,性能和便攜性使牀邊的護理專業人員能夠獲得完整的診斷解決方案,包括在醫院內外。 創新技術也廣泛用於社區母嬰護理計劃,爲包括肯尼亞計劃在內的全球未得到服務的社區提供了高品質醫療保健。

For more information on the award-winning Philips Handheld Ultrasound – Lumify – and its tele-ultrasound capabilities (Lumify with Collaboration Live powered by Reacts), visit Philips point-of-care ultrasound for the latest on high-quality portable imaging.

有關屢獲殊榮的飛利浦手持式超聲 - Lumify - 及其遠程超聲能力(由Reacts提供的Lumify with Collaboration Live)的更多信息,請訪問飛利浦點式超聲,以了解便攜式超聲的最新信息。

[1] Pulse Wave Doppler measurement is currently available on the Android Lumify app. Availability on the Apple iOS/ iPad iOS Lumify app is scheduled for the future.

脈搏波多普勒測量目前可在Android Lumify應用程序上使用。 Apple iOS / iPad iOS Lumify應用程序的可用性將來也有計劃。

For further information, please contact:

如需更多信息,請聯繫:

Kathy O'Reilly
Philips Global Press Office
Tel. : +1 978-221-8919
E-mail : kathy.oreilly@philips.com
Twitter: @kathyoreilly

Kathy O'Reilly
飛利浦全球新聞中心
電話:+1 978-221-8919
電子郵件:kathy.oreilly@philips.com
Twitter:@kathyoreilly

About Royal Philips

關於飛利浦

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

全球領先的健康科技公司飛利浦(紐交所:PHG,AEX:PHIA),專注於改善人們的健康和福祉,並在健康各個環節上實現更好的結果 - 從健康生活和預防,到診斷,治療和家庭護理。飛利浦利用先進技術和深入的臨床和消費者洞察力提供集成解決方案。總部位於荷蘭,該公司是診斷成像,圖像引導治療,患者監測和健康信息學以及消費者健康和家庭護理領域的領先者。飛利浦2021年銷售額爲172億歐元,員工約78,000人,在100多個國家提供銷售和服務 。有關飛利浦的新聞,請訪問。

Attachments

附件

  • Man undergoing ultrasound in ED
  • Product shot of Philips Lumify handheld ultrasound
  • 接受超聲檢查的男子
  • 飛利浦Lumify手持式超聲波產品照片

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論